OrganiGram Holdings Inc.
Q4 2020 Earnings Call Transcript

Published: 30 Nov 2020

[Operator:]

Good morning. My name is Michelle, and I'll be your conference operator today. At this time, I would like to welcome everyone to OrganiGram Holdings Inc.'s Fourth Quarter Full-Year 2020 Earnings Conference Call. As a reminder, this conference call is being recorded, and a replay will be available on OrganiGram's website. At this time, I would like to introduce Amy Schwalm, Vice President, Investor Relations. Please go ahead.

[Amy Schwalm:]

Thank you, Michelle. Joining me today are OrganiGram's Chief Executive Officer, Greg Engel; Chief Financial Officer, Derrick West; and our Chief Strategy Officer, Paolo de Luca. Before we begin, I would like to remind you that today's call will include estimates and other forward-looking information from which our actual results could differ. Please review the cautionary language in today's press release regarding various factors, assumptions and risks that could cause our actual results to differ. Furthermore, during this call, we will refer to certain non-IFRS measures, including adjusted EBITDA and adjusted gross margin. These measures do not have any standardized meaning under IFRS, and our approach in calculating these measures may differ from that of other issuers, and so may not be directly comparable. Please see today's earnings report for more information about these measures. I will now hand the call over to Greg.

[Greg Engel:]

Thanks, Amy. Good morning, and thank you for joining us today. This morning we reported our fourth quarter and full-year fiscal 2020 results for the period ended August 31. For the full year, gross revenue was $103.4 million; and we grew net revenue, which excludes our excise taxes to approximately $87 million. We're also very pleased to report positive adjusted EBITDA for the second year in a row. Most of our discussion today will be centered on our Q4 results as the first three quarters of the year have been addressed in past calls. Since we last spoke with you in July, our product portfolio has changed quite dramatically as we said it would. We've launched 40 new SKUs, including some novel products across a number of categories and segments, and there's still more to come. At the same time, this is all being against the backdrop of meaningful growth for the Canadian adult Rec market. It's been exciting to do this as we continue to plant the seeds for long-term growth and challenges presented by the global pandemic. Our Q4 2020 net revenue grew 25% from the prior year period and 13% from Q3 2020. We had higher flower sales in Q4 2020 as the large format value segment continued to grow and our expanded offerings in this segment resonated well with consumers. And of course, Rec 2.0 sales contributed to our growth as a year ago the products were not yet legal. Lastly, we were extremely pleased to make our first shipment to Israel under our supply agreement with Canndoc, a leading Israeli medical cannabis producer. To date, this is OrganiGram's largest international deal, and we're Canndoc's exclusive supplier of indoor grown cannabis. As you may know, the Israeli Ministry of Health recently amended its quality standards for imported medical cannabis.

[Derrick West:]

Thank you, Greg. I will start with our financial position. As Greg just mentioned, we recently closed an underwritten public offering of approximately 37.4 million units, including exercising the over-allotment option at a price of a $1.85 per unit. We expect to use the net proceeds for working capital and other general corporate purposes with the majority of it being used to pay down our term loan balance. The latter was agreed as part of an amendment and restatement of our credit facility, which we just completed on Friday and it's now available on SEDAR. On December 1st, tomorrow, we will use the proceeds from the offering to repay $55 million on our term loan to reduce the balance to $60 million from its current $115 million. After this term loan repayment is completed on December 1st and excluding the $8 million restricted investment on a pro forma basis, we would have $80 million in cash and short-term investments and $60 million in long-term debt. Turning to our results for Q4. Gross revenue increased 32% to $25.4 million from $19.2 million in the same prior year period. Net revenue grew 25% to $20.4 million from $16.3 million in the same prior period. As Greg mentioned, higher flower sales, international sales and Rec 2.0 revenue were among the largest contributors to this increase. We also recorded a lower sales provision for returns and price adjustments of $2.2 million then as compared to $3.7 million in Q4 as compared to Q4 2019 comparison period. Q4 2020 cost of sales was $29 million, which increased from $15.5 million in the same prior year quarter, primarily due to higher sales volumes at a non-cash inventory provision of $11.1 million for excess and unsalable inventory. Of the $11.1 million, $8.3 million related to excess trim and concentrate, and $2.8 million consisted of adjustments to net realizable value.

[Greg Engel:]

Thanks, Derrick. And I just want to clarify one comment Derrick had made. So the adjusted gross margin was $6.2 million, so just want to clarify that. So looking ahead, we remain positive on the prospects for the industry and OrganiGram. The annualized run rate of the Canadian adult-use Rec market was estimated to be a record $3.1 billion based on the most recent data available from Stats Canada for September 2020. This is an increase of approximately 109% from September, 2019. There are a number of factors creating tailwinds to industry growth. A large factor is the much anticipated increase in the number of retail stores in Canada. Since July, the store count in the provinces grew by 33% driven by Ontario's cannabis retail store -- stores growing at 140%. And Ontario is now on pace to add up to 40 stores per month and sits close to 250 stores right now. So you can see that there is material growth still expected. The legalization of Rec 2.0 is another big tailwind. Product forms in these categories are still being rolled out with new SKUs bringing enthusiasm to the legal market. Consumers are very much still in the exploratory stage and willing to experiment as a broader selection and new product forms such as our RE

[Operator:]

Your first question comes from Aaron Gerry from Alliance Global. Your line is open.

[Aaron Grey:]

Hi, good morning and thanks for the questions. So first one for me, specifically on the vape segment, it looks like quarter-over-quarter revenues did come down a little bit. So, I just wanted to know if you could kind of talk about the trends you're seeing there. Obviously, it's been a pretty competitive category. So just any further color in terms of the drivers which may be impacting you guys and some pricing pressure on the competition there, and more on kind of how you see that evolving for you guys? Thanks.

[Greg Engel:]

Yes. Thanks Aaron for the question. Yes, so we -- I mean, certainly we're one of the companies that offered a fulsome vape portfolio, so having a premium mainstream and a value offering, we have seen more competition come into the marketplace and with that we have had to take some pricing adjustments as well. I think -- again, as we've seen with dry flower, consumers are looking at times to try new products. So that has put, but I mean, certainly we're very excited about certainly our 510 cartridges continue to form very, very well, and we're excited about the upcoming launch of our 1 gram in this next quarter, which we believe has an ability to really have an impact on the market because of the success we've seen in 1 gram in U.S state markets.

[Aaron Grey:]

Okay. Great. Thanks for that color. And then just the second one from me before I pass it on. You spoke about the increase brick and mortar that we’re beginning to see and Canada up 30% since July. So, I would just like to get some commentary in terms of how you think that comes into your plan to more fully utilize your cultivation space, especially we start to see 40 stores per month in Ontario, like you just mentioned. And then just like any color we might be able to get in terms of the first quarter now that we are pretty well through it, in terms of how that might've come through the top line in terms of seeing the benefit of the increased brick and mortar there. Thank you.

[Greg Engel:]

Yes, I think so. We're -- first of all, on the kind of expansion of the Rec space, I mean, one of the things for us and I alluded to this in the call is that we are looking at starting to increase our cultivation production -- and production. We've got space that's not being fully utilized at this point and certainly as the market demand is growing and increasing, we are right in the midst right now looking at plans to start to scale back up. So that would involve potentially bringing in some additional staff back in for both cultivation and downstream processing. And it was one of the impacts certainly that impacted us in Q4 was we were juggling between one area and another area in terms of packaging. So, you hit the nail on the head in terms of we've got the capacity. So now it's the time to start to bring that on. As far as Q1, I guess the comments I would make is we are still in the midst of the portfolio revitalization and we've got new SKUs coming to market. We have had, as I said in the call, we've had still some stock outs and certainly some lost sales opportunities in the near term. But again, we are excited to bring those new products into market not only for the ones we've brought in Q1, but also into Q2. So beyond that, I wouldn't give any kind of guidance on Q1 at this point.

[Aaron Grey:]

Great. Thanks. I will jump back in the queue.

[Operator:]

And the next question comes from David Kideckel from ATB Capital Markets. Your line is open.

[David Kideckel:]

Hi, good morning. Thanks for taking my question and congrats on the quarter. I just wanted to go into your international component of revenue for a second and tie that back to flower as well in Canada. So, in reading through some of your financial statements, we're looking at revenues in Israel, think just north of $3 million. So, the remainder would be mostly 1.0 products in Canada, and mostly flower, we think as you've indicated in your prepared remarks and press release. So, I'm just wondering moving forward, how important and significant internationally is Israel, in particular, going to be for you? I get that you have the exclusive supply agreement with Canndoc. That said, Israel is relatively as you know, Greg and others, a small market, lots of competition, et cetera. So just trying to understand how important should we be -- how should we be thinking about Israel moving forward as an overall line item from a revenue perspective. Thanks.

[Greg Engel:]

Yes. Thanks, David for your question. Yes, so I think a couple of things I would say on Israel. So again, just to clarify, we're the exclusive supplier of indoor flower. So that's the product line that we provide to them. There has been some recent changes in Israel in terms of their medical cannabis systems. So we're working to ensure that we're in a position to continue to supply and we've identified an appropriate path for that. We've had great success with the product and that we have sold in there; and certainly one of the strains is already sold out. And so, we see Israel as a market that will continue to grow. While there is a lot of competition, we also struck this deal with Canndoc as a possible path for them to work to process product in the future because of their certification and to be able to sell into other European markets. So, the agreement is twofold. It's to focus on the Israeli market, but it's also for potential access to the European market via Canndoc as a partner. So you've got to -- I think there's two ways to look at it from that perspective. And now the other point just to your first part of your question. Yes, I mean, flower continues to be very important part of our market which is why we've invested in new genetics, and we've been spending a lot of time on bringing new genetics and new offerings to the market, higher THC products, a broader variety as we've seen consistently where consumers more like a craft beer type market where cannabis consumers are looking to try different and new products on an ongoing basis. So we continue to invest in that area.

[David Kideckel:]

Thanks for that color. Very helpful. And my second question, I want to go back to Hyasynth for a second. And if I heard you correctly, Greg, you had mentioned CBDa is one of the precursor cannabinoids there. I'm just wondering, does this mean you're going to start leveraging that cannabinoid first in some of your 2.0 products or is it CBD and whichever cannabinoid it is, I guess my overall question for on the issue of biologic -- sorry, on biosynthesis is which 2.0 products do you think are most amenable right off the get-go for a biosynthetically derived cannabinoids. Thanks.

[Greg Engel:]

Yes, it's a great question, David. I mean, so -- really excited. Again, it's important to note that Hyasynth, this was the first as far as we're aware of and they're aware of the first successful commercial sale production and sale of any cannabinoid produced through biosynthesis and they had a potential purchaser buyer that was interested in CBDa. So that was the product they ended up producing. Right now their focus in discussions with Hyasynth is they have 23 cannabinoids in their portfolio. 19 of those are minor cannabinoids, I think each uniquely positioned. And I think I've mentioned this on previous calls, where we're really excited about in the future, I think there's two paths for biosynthesis. One is producing a pure major cannabinoid for potential use in products and not only products that we would potentially produce, but possible partners that Hyasynth could partner with in other industries. But I think more importantly, the Meyer cannabinoids and certainly there's a number of them that we are looking at that when -- and I'll give an example of THCV, for example, where THCV has similar effects to THC, but does not necessarily induce an appetite in the same manner at least from anecdotal reports. So I think there's a lot of opportunities for some of these minor cannabinoids in the adult Rec market.

[David Kideckel:]

Okay. Thanks for that and congrats on the quarter. I'll hop back in the queue.

[Operator:]

And your next question will come from Andrew Partheniou from Stifel GMP. Your line is open.

[Andrew Partheniou:]

Thanks for taking my questions. Maybe if we could discuss the new SKUs that you guys have rolled out and the ones that are expected to come. Could you provide any kind of metrics on how well those SKUs have performed? I know you've mentioned that some of them sold extremely well and has had stock outs, but wondering if you get -- to get a little -- could give a little bit more color? And how should we think about that? Should we -- going forward, should we kind of be expecting that this had maybe started off with relatively lower volumes and this will continue to wrap up or was this more of a step change for you?

[Greg Engel:]

Yes and thanks for the question, Andrew. I think the way to look at it in the same way in the past where we've brought a few new SKUs in, right? So we bring the offerings to market. So in this place we had three very specific dried flowers SKUs, for example. We look to see what market responses. We're planning for increased production around the SKUs, but certainly when we see a great response, like in the past with our limelight, we doubled down or quadrupled down on production of that strain, right? Really good response. So --and there's no question that’s been the case here. And one of the challenges when you're bringing new flower products in particular and even new SKUs to market is there is a timeline to get listings in different provinces as you know, so you're -- what impact you're seeing from the market, so getting that feedback is variable. But certainly that is our plan, right, to bring those new SKUs in, the ones that are performed well, we'll continue to increase production on them and the ones that didn't perform as well, we'll reduce cultivation on them and pivot to other items. So in addition to the three recent launches of new strains, we've got additional strains coming up in Q2 and then into Q3. So -- but, yes, I think it's important to continue to supply is that basic products like our limelight, for example is our top selling flower product and continues to be, which has been great. So -- but again, I think there's opportunities for some of these new strains, in particular, the ones that are unique and or high THC to really position themselves well in the marketplace.

[Andrew Partheniou:]

Thanks for that additional color. And maybe going on a similar topic is, it's just on your Phase 5 expansion. Wondering if you could give any updates on that and kind of what needs to happen in order to get some of your hydrocarbon extraction up and running and products on the shelves?

[Greg Engel:]

Yes, we’re -- the area is fully licensed and certainly our expanded CO2 extraction is we're up and running in that space now. We are still working through the commissioning process on the hydrocarbon extraction. So I can't give a definitive target, but our team is working hard to look to bring those products to market. But again it is dependent upon commissioning, which as you can imagine there have been some challenges with throughout the last 9 months with COVID to getting through commission. We've been successful in the past with commissioning new equipment, for example on RE

[Andrew Partheniou:]

Thanks for that additional color. I'll get back in the queue.

[Operator:]

And your next question will come from Adam Buckham from Scotiabank. Your line is open.

[Adam Buckham:]

Good morning. Thanks for taking my questions. So I just wanted to start with maybe talking about production output versus demand. So there's some commentary around this missed opportunities when it came to POS in the queue, and also how you might be looking to increase staff to help resolve these issues. And we think about the bottleneck, is it on the packaging side or was fiscal Q3's decreasing output a partial driver of best? And then maybe more broadly when we think about the current output of roughly 44,000 kgs per year, is that aligned to where you think near-term demand is? Or do you think -- do you see the need to increase output further?

[Greg Engel:]

Yes, that's a great question, Adam. So I would say, it certainly has been -- it's a combination of both in terms of cultivation and levels of cultivation. And the one thing to keep in mind as well is that when you're planning cultivation, that's you're planning 20 to 18 weeks out from when the product actually is available. So some of those near-term PO misses were just the alignment on this -- on the strains and which product was available as we see a continually dynamically shifting market. So again, it's important for us to get consumer feedback and be able to quickly make sure that we're bringing the right product to market. So -- and so the bottleneck has been a combination of cultivation, but also staffing certainly on a packaging and processing side. One of the positives we have seen, if you can say there are any positives related to COVID-19 is that we have gotten more efficient, we are able to do more with fewer people. We've improved processes quite dramatically because we've had to focus on how do we operate in a leaner environment and in a safe environment for our employees, which is really important. So I think ramping back up to some degree is important. And at the same time, you're always going to have some overage of product in terms of production. I mean, one advantage we did have and do have is that we have some sufficient working capital to go through in the quarter, but at the same time, it's not always the -- in terms of inventory, it's not always the strain that are in high demand. And I mean, that's always the challenge to balance. So I think when we talk about ramping back up, we're talking about slowly over time looking to kind of bring some of the facility back online.

[Adam Buckham:]

Okay. That's great color. And secondly, I just wanted to touch on the commentary on Israel. Are you able to give any color on expected timing of the remediation plans? And were you able to get some shipments out in fiscal Q1, or did that change your regulation pushes out into fiscal Q2?

[Greg Engel:]

Yes. So, I mean, I can confirm we did not have a shipment in Q1 into Israel. But we -- and I can't necessarily give a timing target here. I mean, certainly we're confident and so as Canndoc and working with the Israeli government that we have an appropriate path and a solution going forward. So we expect and hope to be able to do that within Q2. But again, it's contingent upon the Israeli government as well as working with some inspectors as well to do things remotely. So that's going to take some time, but certainly hopefully we can work through that.

[Adam Buckham:]

Okay, great. Thanks.

[Operator:]

And your next question will come from Graeme Kreindler from Eight Capital. Your line is open.

[Graeme Kreindler:]

Hi. Good morning and thank you for taking my questions. Maybe as a follow-up to what was just being discussed there with respect to the international market and taking the previous comments with respect to some of the staffing levels and other efficiencies that you're looking to increase throughout fiscal 2021. To me, that sounds like it looks like Q2 might be the real inflection point that we should be looking at in terms of the new SKUs launching, whether it's the 40 that had been launched the other 18 you’re looking to launch in Q1. And then a potential restart of international shipments starting in Q2. Is my thinking correct there? I'd appreciate some further commentary with respect to the cadence of potential revenue growth. Thank you very much.

[Greg Engel:]

Yes, Graeme thanks for the question. I mean, what I would comment on it -- so first of all, just to clarify, the 40 SKU launches since July were Q4 and Q1, so -- and then Q2 we'll have an additional 18. So, yes, there is additional growth that we're expecting, for example, the Trailblazer 1 gram vape cart that I mentioned to come in Q2. So I think, again, we are optimistic about the growth coming in the near-term. Again, we historically don't give guidance in terms of revenue, but I think as we're seeing the impact of new -- of the new SKU launches and continue to see new product launches, even our RE

[Graeme Kreindler:]

Okay, understood. I appreciate the color there. Then just as a follow-up with respect to the gross margin, there was $11 million of inventory that was written off or impaired this quarter, impacting that gross margin. I was just wondering if you could provide some more details on what sorts of products were included within that $11 million charge. And at this point, does the company feel comfortable in terms of where its inventory position is sitting in terms of how things are costed within there that it's through the bulk of these charges. Thank you.

[Greg Engel:]

Yes, it's a great question, Graeme. Maybe I'll turn it over to Derrick to answer that question.

[Derrick West:]

Yes. Thank you, Greg. Yes, for the fourth quarter, there was $11.1 million in overall provisions around inventory, including adjustments for net realizable value. Of that $11.1 million, $8.3 million is pretty much contained to extract materials in terms of the concentrates and the trim. So that was the bulk of it. And historically the company had built up a certain quantum in regards to these categories. And -- but I can't say -- but at this time we stopped harvesting the trim and the prior adjustments and the carrying value of the trim was a significant contributor. As I look at the balance sheet, our inventory and bio assets now have declined 37% then as compared to a year ago and 28% compared to our Q3, 2020. And this has reduced our exposure to future valuation adjustments that would negatively impact our future gross margins. In the interim, it's just very -- it's unreasonable to expect that there's not going to be some ongoing non-cash adjustments for excess aged inventory and net realizable value adjustments due to the combination of price compression in the market combined with the ongoing changes to consumer preferences. Having said that, we do feel that over the last few quarters, we've had a heightened review of these matters and with the provisions now taken, we are comfortable with the carrying values that are on the balance sheet at this time.

[Graeme Kreindler:]

Okay. Understood. Appreciate the color. Thank you very much.

[Operator:]

And your next question will come from Rupesh Parikh from Oppenheimer. Your line is open.

[Rupesh Parikh:]

Good morning. Thanks for taking my question. I also wanted to follow-up on gross margins. The near-term, is it fair to think about the 30% level as maybe a base to build off of? And then longer term, just thinking about how you guys are thinking about the longer term scaling of gross margins from here?

[Greg Engel:]

Yes. Maybe Rupesh thanks for the call or the question. I'll maybe let Derrick answer that one as well.

[Derrick West:]

Yes. For fiscal year '20, our adjusted gross margin was 33%. But as you correctly note, the Q4 period that we've just filed was -- had an adjusted gross margin of 30%. This has had the impact of significant price reductions in the market that it has occurred over the current fiscal year, and also includes a certain level of production inefficiencies. But to some extent we do believe that it should somewhat persist as we continue to launch 2.0 products and continue on the learning curve to optimize production. But the Q4 30% margin, does reflect them -- where it was with regards to the pricing in the market and our production levels. And so at this time it's a fair indicator.

[Rupesh Parikh:]

Okay, great. Any commentary just longer-term scaling gross margins from here as you look forward?

[Derrick West:]

Yes, we -- I would say that we've stayed away from providing any guidance between long-term target for gross margins, just as a consequence of it's too dynamic of an industry with increasing competition, uncertainty, especially related to the duration and impact of the pandemic. And again, we do believe we do have the potential to optimize our production and efficiencies as we work through the learning curve, particularly related to 2.0 products and improving the packaging costs that Greg was talking about earlier. And as we moved to a larger format offerings on the 20 gram with repack pre-rolls. But it's difficult, it's a very ever changing dynamic market. And so that's the most we could provide for guidance at this point.

[Rupesh Parikh:]

Okay, great. Thank you.

[Operator:]

And your next question will come from John Zamparo from CIBC. Your line is open.

[John Zamparo:]

Hey, thanks. Good morning. I just want to stick with that same topic of gross margin over the next few quarters, and then maybe we can simplify it a bit. But particularly as it relates to new SKUs and Shred in particular, those seem like that's quite popular. I'm trying to get a sense of the impact of those, and maybe the way we can frame this is if there's no further pricing compression in the market, is it fair to say that the cost optimization efforts you put in so far and the higher volumes you're expecting and the new SKUs you're launching that in a similar environment in terms of pricing that you'd see margin growth.

[Greg Engel:]

Again, maybe Derrick answer that question.

[Derrick West:]

Yes. Well, I guess as the question is framed, sure, if there's no changes in the pricing in the market as we increase our volumes. Just inherently when you increase your volumes, you do absorb the fixed overhead amounts and have less of the unabsorbed fixed overheads from not operating at capacity, along with improving the efficiency at the facility. So under parameter, yes margins would move up under that scenario.

[John Zamparo:]

Okay. Thanks. And then my follow-up is on Ontario. Greg, you mentioned your optimism about this province, just because of the store growth, which I think is fair. Can you talk about your performance in Ontario relative to other provinces, whether it was in Q4 or in Q1 and even without giving specific numbers. Just trying to get a sense of, if you think you're adequately participating in the industry growth in the province. Thanks.

[Greg Engel:]

Yes, it's a great question, John. I think Ontario we see is probably the most competitive market across the country. And you know we certainly see more SKUs listed in Ontario than any other province. And so when I think -- because of the size of the market, it is the one where we've seen the most significant stock-outs, which in one hand you can look at it and say is good news in terms of there's product and demand. But it has impacted us in terms of market share and revenue because of the size of the market growth. I mean, we knew the market was going to grow, but certainly the rate -- again, as you -- if you think about the timelines in the cannabis space, the rate of growth kept moving up at a faster rate than anticipated. And with kind of a 16-week -- 20 to 16-week planning cycle for certain product types being able to just -- on the other hand, it's good news. And as again, that market growth I think is strong and will continue and even with COVID and some of the restrictions put in place in the Toronto and regions, I think we'll continue to see good growth. I know on the construction side and the licensing side, they expect that to continue at the same pace. So -- but we were impacted, I would say in Ontario a little more than other provinces with stock-outs and because of success as you said, Shred, for example, which was alluded to earlier, I mean was one of the highest demand products through the OCS website and through many stores that carried it in the first few weeks of launch. And so certainly for us to continue to supply that as we were bringing it into other provinces that was higher than expected demand for us. So again, you get strong growth and then you're in a position where you're not able to resupply the market quickly, but again we're adjusting accordingly and to be in a position to continue to supply that on an ongoing basis and have it available, which I think is critical.

[John Zamparo:]

Okay. That's helpful. Thank you very much.

[Operator:]

And your next question comes from Matt Bottomley from Canaccord Genuity. Your line is open.

[Matt Bottomley:]

Yes. Thank you very much. Good morning, everyone. Just wanted to expand a bit further on John's prior question there. It was sort of framed around Ontario. But when you look at the overall market growth, certainly at the retail level and you've mentioned this in your outlook, you use the one month of September, it looks like it's about a $3 billion market. Do you have any color on dynamics of how much LPs as a whole are sort of losing their market share to the provincial buyers, pricing at the retail level are coming down at the same degree. I imagine more of the economics might be going to the provinces and some of the wholly-owned retailers, if there's a dynamic there to explore. And then if you can give any color on the product SKUs and format that you're focused on, maybe the edibles side and the beverage side of the powder beverage side. I know it's very nascent right now, but where you think you rank in the overall Canadian landscape as those obviously have longer term growth profiles and what we're seeing in dry powder?

[Greg Engel:]

Yes, I mean, thanks for the question, Matt. I think when you look at the market, I mean, certainly and I'll look back over the last 6 months or 12 months even, for example, when pricing reductions come into place and those predominantly are shared with the province. So you're -- it's not just the company taking a pricing reduction, it's shared. So in many aspects, some of the strategies are done jointly with provinces to move product or to react to competition. So I think there is some sharing that happens even on that side of things. I think we're seeing an evolving landscape. I mean, we keep hearing discussions about how some of the systems may change in the foreseeable future. I mean, we know for example, new Brunswick is looking at going to a private tender for their program. There's some discussions about Alberta shifting some of their models. So I think it -- it's an evolving landscape and one that you've got to be flexible to work with. I think for us, one of the things that's been really positive is we've seen some consolidation on the retail side. And so certainly the partnerships in the companies where there has been consolidation or partners that we have strong ongoing relationships historically with, so that's a positive and those are national presences in both cases with the consolidation that's happened. So that's a positive for us. I think to get to the second part of your question, when you look at expanded offerings, I think in the near-term, again, getting out in the vape portfolio, getting out a 1 gram is important. We've seen a competitor just launched last week and we need to get that product out to market in this quarter. We had plans to do so. But again, sometimes those are impacted by COVID and some of the equipment supplies and things like that. But -- and RE

[Matt Bottomley:]

Appreciate that. And then just a quick follow-up. Maybe overall, just the sort of management risk assessment, or maybe high level view on as this market continues to expand. So that $3.1 billion number, I think it's very encouraging, but when you look at the LP landscape overall, and it's not really dominated by profitability at this point, where do you see the opportunity to really lock in whether it's margin or things that are more specific to organic gram strategy and core competency plan? We see a lot of price monetization in dry flower. Is this a risk that the vape pen category given the high competition could see a similar dynamic in the next year here. And as the market gets closer and closer to, I think that overall headline number in terms of market size might be close to 10 billion, and we'll see where that fall. Where do you assess the risk of subsequent product categories, potentially being commoditized at the overall macro that the industry continues to grow pretty healthy.

[Greg Engel:]

Yes, I think -- look, it's a great question. I think to some degree we've already seen the pricing changes happen in the vape market, right? We early on there was limited competition. Then as more products came into market, we saw pricing. And again, as I mentioned, we did share some of that pricing reductions that we took with the provincial partners and or private retailer, but we're I mean, really with the provincial partners on the distribution side, I think what's important though, is for companies like OrganiGram is you're improving your efficiency, right? So as the pricing compression has happened in flower and you go to larger volume SKUs, certainly your packaging costs go down pretty dramatically. And I think on 2.0 products, it's the same as you're producing more of the product, you're producing it more frequently. You're doing it more efficiently, more effectively. So, while you're getting some price pressure, but I think it's we've talked about this all along. I mean, when we spoke about, as a company, part of our focus is to bring quality differentiator products. And even, for example, our Trailblazer Snax chocolate bar, which participates in the value category arguably is one of the best tasting and differentiated chocolates in the market. I mean, it's a five-piece bar in 42 grams, each piece is filled kind of independently. So it does allow consumers some flexibility in terms of dosing. It's not just one big bar where you may not have a homogeneous kind of distribution of cannabinoids in it. But again, I think it's important to continue to focus on the new products and not just new flower offerings for that consumer that's always looking for something new and unique and also the differentiator products you can bring to market like RE

[Matt Bottomley:]

Great. Appreciate all of that. Thanks all.

[Operator:]

And your next question will come from Rahul Sarugaser from Raymond James. Your line is open.

[Unidentified Analyst:]

Hey, Greg, and Derrick and Amy. This is Mike in for Rahul today. There's a couple of questions from me. So I know we've talked a lot about production and how we can enhance efficiencies going forward. I'm wondering if, and I’m looking at your yield per plant features year-over-year, and they seem to have gone down from about 150 grams per plant to around a 100 at the end of this year. Is this a problem that you can resolve with staffing and how important do you see the sort of yield per plant issue as it flows into the rest of your business?

[Greg Engel:]

Yes, maybe I'll start off and answer that Mike -- Michael, and then if Derrick has anything to add. I mean, so certainly two things to keep in mind. So as on a per plant basis we stopped keeping trim by-product a couple of quarters ago, right? We had sufficient extract inventory and sufficient extractable material. So that's roughly 30% production drop in kind of yield per plant, right? So if you look at it from that factor. And then we've been focused on increasing THC with some experimentation on different techniques, different styles, also different strains. Some of the strains, as you know, certainly you've been to our facility, some strains have a higher yield per plant, others have a lower yield per plant, and it's finding that balance on a THC and yield basis right, where you're still calling . I think as -- again, the focus for us has to be, I mean, when we speak about increasing staffing at all, we're talking modest increase in staffing, right. Just bringing a limited number of people back into the facility and increasing our staffing. But I think I wouldn't say that's going to have an impact on yield and plant care per se. It's more about the genetics who we choose to grow. And I think that's the most important one. So hopefully that answers your question.

[Unidentified Analyst:]

Yes. That's really helpful. And just a thing on the topic of staffing, I mean, in new Brunswick recently that you've seen some enhanced COVID related restrictions like the Atlantic bubble recently. Are you seeing sort of the recent uptick in cases in new Brunswick specifically affecting your operations or your capacity to re-staff even modestly?

[Greg Engel:]

No, it's a great question. I mean, so certainly we have worked closely with the government and actually we actually had a spot inspection last week where public health were safe and RCMP came in, and they've been visiting sites across the province to ensure kind of safety and protocols are in place and a safe workplace for employees. And they were satisfied with everything they saw on site. So I think what -- yes, we have seen an increase in the province, but I think for us, we've been focused since the early days of COVID to make sure that we could and do have a safe workplace for employees. And I think our employees appreciate that. And it's been a big part of what we do. So to date, it has not had an impact on our facility and our operations. Again, I think the greater impact of COVID sometimes is more equipment and/or getting third-party contractors into to do work on equipment and things like that, which has been a challenge. So …

[Unidentified Analyst:]

Got you. That's terrific. And if I could just have one more in there, if we could refocus closely on biosynthesis and Hyasynth typically and your recent investment and their recent announcement of recent CA is a big deal in this space. How would you see partnering with Hyasynth as a potential route into the United States, given that bio manufacturing through contract research -- or contract manufacturers can happen almost anywhere.

[Greg Engel:]

Yes, it's interesting. And Michael, I'm not sure if you've spoken to Kevin or not, but actually that this first production and sale was actually completed in the U.S. So they are working with a contract site there, they transferred over their yeast strains and enzymes to do it often -- do an optimization process. So yes, I think the big difference with biosynthesis versus cannabis plant production is, it doesn't have to be country-specific and certainly there's lots of opportunities for Hyasynth to operate either in any jurisdiction where it's legal and or to operate in jurisdictions and do product transfers right of pure cannabinoids and certainly ones that don't have the same control mechanisms on them as others at this point, or in the future ones that there's been changes. So I think that is a big part of their strategy right now.

[Unidentified Analyst:]

That's really helpful. Thank you very much.

[Operator:]

And your next question comes from Douglas Miehm from RBC Capital Markets. Your line is open.

[Douglas Miehm:]

Yes. Good morning. Just a couple of quick questions. Number one, Greg, you're, really close to the industry, and I'm just wondering what your thoughts are on M&A right now and what you see unfolding in Canada, but also North and South of the border with respect to the Canadian market. Yes. I mean, we are what we have seen some consolidation now in the retail space, and I think that we expect that to consider potentially Doug. But I think when we look at this space and I've said this publicly before, I mean, we are continuously approached by banks and or companies directly where companies are looking to be acquired or have a strategic investment into them. And I think one of the challenges is always when you evaluate those companies is looking at what's their differentiator, what's their innovation, what's their kind of brand. I mean, if you have all three of those and or a couple of those that can be quite unique, then certainly something to evaluate. So I think that's the challenge to be frank in the spaces. There are many companies that don't really have that differentiation. So I think it's one of the things we focus on when we assess people is what is the differentiation? How do you supplement? I mean, certainly there's public. Public companies, synergies that could happen in any MA activity. But I think the more important things along with that are, how did the two companies combined and what are their synergies in terms of the market opportunity. So North and South of the border, I think that's still very much dependent upon what happens in the U.S and I think, if the Republicans control the Senate, with these two upcoming run-off elections and, in Georgia that sets one tone. If it democrats were able to garner both those seats that might send another direction. So, we'll see what happens.

[Douglas Miehm:]

Okay. And then just -- I didn't want to continue on with the U.S. market. And you said you are doing some work about how that could unfold and how you're going to move as a result of that. Can you elaborate on what the company might be thinking. We've seen other companies move into the market, and I'm just wondering, given your relationship with the company in Colorado, how you're thinking about it.

[Greg Engel:]

Yes. I mean, look, we continue to monitor the U.S. and certainly one of our key staff is on a board out in the U.S. in the industry. And I think we've certainly been a big part of our focus, even on the GR side is to kind of keep, keep our finger on the pulse of what's happening there. I think when you look at the market as a Canadian company, that's still listed, but we -- in the near-term, our focus is, are there CBD opportunities? And I think that would potentially be a way to enter the marketplace in a legal fashion. But we do follow THC as well. I think part of our focus as well as been very much about creating innovative products. So for example, our RE

[Douglas Miehm:]

Perfect. Thanks very much.

[Operator:]

Thank you, everyone. This will bring us to the end of our Q&A session today. I would like to thank everyone for joining our conference call today. This will conclude our conference call. You may now disconnect.